Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 04, 2026
BWX Technologies (BWXT): Q1 2026 Earnings Preview – Expectations and Key Watch Items

BWX Technologies (BWXT): Q1 2026 Earnings Preview – Expectations and Key Watch Items

Key Takeaways

  • Analysts expect Q1 2026 EPS of $0.92 to $0.93, a modest 1-2% increase year-over-year from $0.91 in Q1 2025.
  • Consensus revenue estimate around $830 million, implying over 20% growth from the prior-year quarter.
  • BWXT recently initiated strong 2026 guidance: revenue of approximately $3.75 billion and non-GAAP EPS of $4.55-$4.70.
  • Record backlog and rising nuclear demand in government and commercial segments are key positives.
  • The company has a history of beating EPS estimates, including a strong Q4 2025 performance.
  • Investors will watch for updates on adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and segment growth.

Earnings Context and Why It Matters

BWX Technologies (BWXT), a leader in nuclear components for U.S. naval reactors and expanding into commercial nuclear applications, reports first-quarter 2026 results after market close on May 4, 2026. From what I see, this earnings release carries significant weight amid surging demand for nuclear energy solutions, driven by defense contracts and clean energy initiatives. Following a record 2025 with 18% revenue growth and Q4 non-GAAP EPS of $1.08 (beating estimates), the report will provide insight into progress toward full-year guidance. For investors, it offers a clear view of backlog conversion, margin trends, and commercial nuclear momentum—all critical factors influencing valuation in a sector set for expansion.

Earnings Expectations

Wall Street anticipates first-quarter revenue of approximately $830 million, reflecting robust 20-23% year-over-year growth fueled by government operations (primarily naval nuclear propulsion) and commercial segments. EPS consensus sits at $0.92-$0.93, up slightly from $0.91 last year, with focus on non-GAAP figures excluding one-time items. Key metrics include adjusted EBITDA growth and updates to the multi-year backlog, recently at record levels.

BWXT has beaten EPS estimates in recent quarters, including Q4 2025's $1.08 versus $0.89 expected. Historically, the stock has shown mixed reactions: gains after Q3 2025 but dips post-Q4 despite beats, often tied to guidance perceptions. Investors eye confirmation of 2026 outlook amid supply chain and labor dynamics. To gauge how BWXT compares to peers, I checked it using Tickeron’s AI Screener.

Market Reaction and Investor Sentiment

Heading into earnings, sentiment is cautiously optimistic, buoyed by nuclear sector tailwinds and BWXT's strong 2025 finish. Shares have outperformed the aerospace-defense industry over the past year, reflecting backlog strength. Risks include execution on complex government contracts and commercial ramp-up delays. Post-earnings volatility could hinge on guidance alignment with consensus. One thing that stands out to me is how the stock's resilience ties directly to that record backlog.

Tools for Smarter Analysis: Tickeron’s AI Screener

In my research process, Tickeron’s AI Screener has become a go-to resource. This AI-powered stock and ETF discovery tool lets me filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. I customize scans by industry, market capitalization, technical indicators, price patterns, and performance metrics to pinpoint trade ideas, trending stocks, breakout candidates, and opportunities more efficiently than manual methods. It streamlines my workflow and helps uncover insights I might otherwise miss.

Forward Outlook and Key Factors to Monitor

Following Q1 results, attention will shift to full-year 2026 guidance validation, with revenue targeted at $3.75 billion (high-teens growth) and non-GAAP EPS of $4.55-$4.70. Government Operations, representing the bulk of revenue, should benefit from naval nuclear propulsion demand, while Commercial Operations eyes nuclear fuel and microreactor progress. I’m watching this closely because commercial momentum could be a real differentiator.

Key watches include backlog evolution (recently record-high), adjusted EBITDA margins amid cost inflation, and free cash flow generation. Industry dynamics like U.S. nuclear policy support and international opportunities could provide tailwinds.

Upcoming catalysts encompass contract awards, regulatory updates for advanced reactors, and quarterly segment breakdowns. Balanced cost management will be crucial as supply chain pressures persist. In my view, this positions BWXT well if they execute effectively.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: BWXT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


BWXT's Indicator enters downward trend

The Aroon Indicator for BWXT entered a downward trend on August 07, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 122 similar instances where the Aroon Indicator formed such a pattern. In of the 122 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BWXT as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BWXT turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BWXT's RSI Indicator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BWXT advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .

BWXT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BWXT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.764) is normal, around the industry mean (7.037). P/E Ratio (40.617) is within average values for comparable stocks, (60.208). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.077). Dividend Yield (0.007) settles around the average of (0.017) among similar stocks. P/S Ratio (4.102) is also within normal values, averaging (20.174).

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 40.4B. The market cap for tickers in the group ranges from 4.49 to 1.81T. SPCX holds the highest valuation in this group at 1.81T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -8%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was -3%. NPK experienced the highest price growth at 7%, while DFSC experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -5% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 68
Price Growth Rating: 55
SMR Rating: 78
Profit Risk Rating: 73
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
BWXT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of components and services to nuclear power industry

Industry AerospaceDefense

Profile
Details
Industry
Aerospace And Defense
Address
800 Main Street
Phone
+1 980 365-4300
Employees
7800
Web
https://www.bwxt.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.